Icosavax is a cutting-edge brand dedicated to developing better vaccines to meet the world's needs. As a clinical-stage company, their primary focus is on creating a new type of vaccine specifically designed to protect vulnerable older adults from various respiratory viruses. What sets Icosavax apart is their innovative use of virus-like particles (VLPs) as the foundation for their vaccines.

These VLPs mimic the structure of viruses, leading to a stronger immune response. Icosavax believes that their VLP technology offers numerous advantages over current modalities, including a more significant immune response, broader coverage against related viral strains and mutations, longer durability, lower incidence of side effects, and easier combinability for multiple targets in a single vaccine. As pioneers in the field, Icosavax invites you to join them in this new era of vaccines.

Explore their VLP technology and be part of their groundbreaking progress